论文部分内容阅读
目的:分析研讨硝苯地平联合厄贝沙坦在社区糖尿病合并高血压疾病中治疗状况。方法:此研究中所研讨的124例患者均随机从我院2014年3月至2016年1月期间所收治的社区糖尿病合并高血压疾病患者中挑选而出,将124例患者依据随机抽签方式分两组,62例对照组接受厄贝沙坦治疗,62例研究组接受硝苯地平联合厄贝沙坦治疗,对比分析其治疗状况。结果:从24h尿微量白蛋白、DBP、SBP指数上来看,研究组比对照组优,组间数据有统计学意义(P<0.05)。研究组治疗总疗效91.94%比对照组80.65%明显要高,组间数据有统计学意义(P<0.05)。两组患者均未出现严重不良反应。结论:临床在治疗社区糖尿病合并高血压疾病时可考虑将硝苯地平和厄贝沙坦药物联合使用,疗效突出,安全性高,推广应用价值大。
Objective: To analyze the treatment of nifedipine combined with irbesartan in community diabetic patients with hypertension. Methods: All 124 patients studied in this study were randomly selected from patients with community-based diabetes mellitus with hypertension who were treated in our hospital from March 2014 to January 2016. 124 patients were randomly selected based on random sampling Two groups, 62 cases of control group received irbesartan treatment, 62 cases of study group received nifedipine combined with irbesartan treatment, comparative analysis of the treatment. Results: From the 24h urinary albumin, DBP, SBP index, the study group than the control group, the data between the two groups was statistically significant (P <0.05). The total effective rate of the study group was 91.94%, which was significantly higher than that of the control group (80.65%). There was significant difference between the two groups (P <0.05). No serious adverse reactions occurred in both groups. Conclusion: The clinical use of nifedipine and irbesartan may be considered in the treatment of diabetes mellitus with hypertension in the community. The combination of nifedipine and irbesartan is superior in efficacy, safety and popularization and application value.